Status:
COMPLETED
Improving Detection and Early Action for HPV-positive Oropharynx Cancer
Lead Sponsor:
Brigham and Women's Hospital
Conditions:
HPV Positive Oropharyngeal Squamous Cell Carcinoma
Eligibility:
All Genders
35+ years
Phase:
NA
Brief Summary
This study aims to determine whether a blood test for HPV DNA can improve diagnosis of HPV-positive oropharynx cancer (HPV-OPC).
Detailed Description
The diagnosis of HPV-OPC is often delayed. In this study, individuals with signs or symptoms potentially related to HPV-OPC, such as unexplained throat pain, tonsil or tongue base asymmetry, or a neck...
Eligibility Criteria
Inclusion
- Neck mass present for \>2 weeks with no signs/symptoms of infection
- Neck mass present for \>2 weeks with signs/symptoms of infection that did not resolve with antibiotic therapy
- Palatine or lingual tonsillar asymmetry on physical exam
- Palatine or lingual tonsillar asymmetry on imaging, including asymmetric FDG uptake in palatine or lingual tonsils on PET-CT scans
- Unexplained throat pain for \>2 weeks that did not resolve with antibiotic therapy
Exclusion
- Known diagnosis of HPV-OPC
Key Trial Info
Start Date :
March 24 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04871490
Start Date
March 24 2021
End Date
December 31 2024
Last Update
February 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02130